current sec report duti releas full-year result
reflect strong end also frame stabl start
guidanc call sale growth although compani opt offer full-
year guidanc manag comment surround limit impact
share thought procedur trend relat china
discuss result also touch procedur relat revenu compani
recogn china term specif product demand china note
experienc acceler purchas pd product compani expect sort
demand emerg near futur compani also comment
stabil procedur within advanc surgeri busi china mention
small busi compani single-digit million annual basi
difficult estim procedur volum trend given small base mention
renal largest busi china although trend busi
illustr what happen hospit region
maintain ww suppli chain face
regard maintain global suppli chain face manufactur
oper reportedli run plan level compani continu assess
mitig disrupt ww activ manag inventori level warehous
stock level transport option raw materi compon part avail
specif given disrupt suppli chain relat china itali compani
mitig disrupt deploy exist inventori provid addit support
aid supplier return product util altern ship method deliveri
expedit work addit supplier addit compani focus
maintain liquid time uncertainti counteract potenti
scenario could occur nearli cash end abil
access credit revolv credit facil management note
electron api made china safeti stock feel comfort
toward late spring enough iv bag predominantli made
 back-up mexico compani continu monitor close raw
restat process complet encourag guidanc
announc current sec report oblig file
compani offer formal guidanc
time due uncertainti pose far experienc
limit impact offer guidanc look encourag reflect
strength stabil specif compani expect sale growth
report basi constant currenc oper basi
believ outsid onetim item benefit outlook
show signific chang underli busi among onetim item
call benefit roughli relat competitor market
advanc surgeri account adjust toward end year tune
roughli adjust ep anticip street
ep project regard number somewhat stale reflect
financi item total approxim cent off-set ep quarter
pleas see page report import disclosur
corpor split posit better focu deliv margin expans
top- bottom-lin growth long term margin progress made
recent year commend howev compani hamper low
single-digit top-lin growth trajectori time medic devic peer routin
gener revenu growth regularli reach high single-digit growth
rate think capabl manag team well balanc sheet
capac pursu higher-yield sale growth opportun via acquisit nevertheless
rate stock market perform believ attract long-term high-
growth revenu driver still larg unidentifi despit compani average-to-
focus support compani
achiev sale
oper cash flow track grow
expect
sale growth exce
oper basi ahead schedul
pipelin opportun acquisit
om expans come
pipelin fail deliv
 fail produc new top-lin
diversifi global healthcar compani product use hospit dialysi
clinic nurs home rehabilit center research laboratori patient home
compani organ six divis renal medic deliveri
nutrit advanc surgeri acut therapi year undergon
major structur chang includ acquir gambro enhanc renal
busi spin bioscienc divis baxalta streamlin
oper transform given work progress statu new
manag team begun method address compani significantli
improv margin profil recent year continu target acceler top-lin growth
opportun accret current margin
stockpil begin us europ relat
come compani see hospit europ
halfway focu still china management comment
see buy pattern in-lin somewhat similar situat sar
sudden stockpil occur compani note front line treatment
key respiratori acut gener infect area product
ccrt iv fluid antibiot pump anesthesia advanc surgeri
busi also see impact request order placement stockpil product
incom increas state feder govern level
capac restrict compani work enhanc cash flow ensur
custom order ration plan carri extra inventori critic product
may stockpil relat broader pandem final regard impact
capit equip sale management discuss hospit current focus
treat patient short term prioriti capit equip purchas may
shift bit mid-to-long term management expect chang buy
sale result mirror pre-announc margin ep expect
revenu result larg mirror sale pre-announc receiv
januari specif compani report revenu reflect report
growth constant currenc growth growth oper basi beat
street forecast estim also compani strongest
quarterli oper sale growth sinc spin-off baxalta
quarterli sale detail look fine sale increas
report oper basi sale increas
report basi constant currenc oper basi
deliv strong sale result across busi unit segment renal sale total
currenc acut therapi sale total constant currenc
januari indic oper margin would exceed previous
commun rang thank strong revenu oper
perform today learn oper margin adjust ep
roughli beat though help cent came
lower-than-expect tax rate
pt revis
decreas price target primarili due contract med-tech
multipl estim reduct appear better posit manag
crisi rel peer complet immun new ep
estim revis account current environ arriv us pt
cowen compani
chg good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recvr gain incom non-controlling inc inc oper ex-intang restructur non-recur gain share estim cowen
figur revenu highlight busi segment mm
cowen compani
cowen compani
year end decemb end decemb end decemb good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recur gain incom non-controlling intang amort inc inc oper ex-intang oper ep includ intang restructur non-recur gain share per cowen
cowen compani
good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex-intang restructur non-recur gain incom non-controlling intang amort incom baxter incom baxter oper ex-intang oper ep includ intang restructur non-recur gain share analysisgross analysistot incom per share cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
compani specif risk includ impact long-act factor viii agent
global share advat franchis limit increas plasma fraction
capac ig franchis time regulatori approv hyq line-extens
bioscienc product develop realiz synergi impact margin
gambro acquisit acquisit exposur emerg market
